Pyxis Oncology’s (PYXS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock.

Separately, Royal Bank of Canada reiterated an “outperform” rating and set a $8.00 target price on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Pyxis Oncology Stock Performance

Shares of PYXS stock opened at $1.23 on Monday. The company has a market capitalization of $76.20 million, a PE ratio of -1.19 and a beta of 1.15. Pyxis Oncology has a 52-week low of $0.83 and a 52-week high of $5.39. The business’s fifty day moving average is $1.05 and its 200 day moving average is $1.60.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06). On average, sell-side analysts forecast that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds have recently added to or reduced their stakes in the company. Barclays PLC raised its holdings in shares of Pyxis Oncology by 275.0% during the 3rd quarter. Barclays PLC now owns 64,089 shares of the company’s stock valued at $235,000 after buying an additional 46,997 shares in the last quarter. American Century Companies Inc. grew its position in Pyxis Oncology by 88.1% during the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company’s stock valued at $468,000 after acquiring an additional 140,498 shares during the last quarter. Caption Management LLC purchased a new position in shares of Pyxis Oncology during the fourth quarter worth approximately $35,000. Renaissance Technologies LLC lifted its holdings in shares of Pyxis Oncology by 83.0% in the 4th quarter. Renaissance Technologies LLC now owns 293,354 shares of the company’s stock worth $458,000 after acquiring an additional 133,018 shares during the last quarter. Finally, Ridgeback Capital Investments L.P. purchased a new stake in shares of Pyxis Oncology in the 4th quarter valued at $560,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.